Read the Latest News

National Academy of Medicine to Conduct a Study on Temporomandibular Disorders

We want you to be among the first to know that because of the advocacy efforts of The TMJ Association, the National Academy of Medicine (NAM) will conduct a first-ever study on Temporomandibular Disorders (TMD).

Dentists in Distress

Fear of the dentist is practically a rite of passage in youth. Growing up, I wasn't exactly afraid of the dentist; rather, any excuse to leave school early was a powerful incentive. These days, I have a more complicated relationship with dentistry: I go to get answers and try to feel better, but I always pop a prophylactic ibuprofen or two in case my jaw protests from the oral gymnastics.

Patients in Los Angeles or New York City Needed for Clinical Study - Comparative Study of Women Considering or Currently Receiving Botox© Injections for TMJ Pain

Are you a woman with "TMJ" pain in facial muscles, who has either: a. recently had Botox© injections for your pain or b. not had Botox© for your pain but has thought about such treatment? If either is true for you, you may qualify for an observational research study centrally administered by the NYU College of Dentistry. It is funded by the National Institutes of Health (NIH). The purpose of this study is to understand potential health risks that may be caused by treating "TMJ pain" with Botox© injections.

Patients Front and Center at the 2018 TMJ Patient-Led RoundTable

It is still all too fresh in the minds of many patients. Fifty years ago, between the 1970s and 1980s, some 10,000 TMJ patients received Vitek jaw implant devices.

Funding Opportunities now available for the NIH Common Fund’s Acute to Chronic Pain Signatures program

The NIH Common Fund's Acute to Chronic Pain Signatures program aims to understand the biological characteristics underlying the transition from acute to chronic pain and what makes some people susceptible and others resilient to the development of chronic pain.

Partnering to Improve Chronic Pain Care

  • Oct 5, 2017

Cutting Edge Science Meeting to End Opioid Crisis - Understanding the Neurobiological Mechanisms of Pain

Partnering to Improve Chronic Pain Care

The National Institutes of Health (NIH) held three meetings this summer with the goal of developing the first public-private partnership (PPP) to develop safe and effective treatments for chronic pain, as well as new treatments for opioid addiction and overdose. The proposed partnership would be a joint effort of the NIH, the U.S. Food and Drug Administration (FDA) and the pharmaceutical and medical device industry. Christin Veasley, Director of the Chronic Pain Research Alliance, an initiative of TMJA, was invited to participate in the third meeting focused on the neurobiology of pain. The meeting was hosted by NIH Director, Dr. Frances Collins and the NIH principal Deputy Director, Dr. Lawrence Tabak. Other attendees included several NIH Institute Directors, clinical and basic scientists in pain research and representatives of pharmaceutical and device companies.

Christin was asked to address chronic pain research from her perspective as a chronic pain patient and patient advocate. She noted that pain receives limited research investment, is frequently dismissed by health care professionals, and is not regarded as a major public health problem, despite being the most prevalent, costly and disabling condition in the U.S. Further, the admission of pain remains a source of stigma for patients and is regarded by society as a sign of weakness.

Christin highlighted issues with the current treatment system, namely the shortage of pain specialists, the dearth of education and training in pain management for primary care physicians and the lack of quality evidence of various therapies. This leads to trial-and-error-based clinical decision making. To improve the care of pain patients, better measures of pain are needed, she stated, along with preclinical models and clinical trials that account for the complexity and individuality of responses to the chronic pain experience. These measures should include an assessment of comorbidities, such as sleep and mood disorders, the loss of functional abilities and health-related quality of life. She emphasized that a precision medicine approach to clarify how genetics, environmental factors and lifestyle interact in an individual pain patient's experience can lead to tailored treatments that can more effectively manage pain. Christin concluded that pain research will greatly benefit from the participation of stakeholders from across the research and clinical translation spectrum, including patients, clinicians and payers.  (Click to view the PowerPoint presentation)

The meeting summary, along with those of the earlier two meetings, can be viewed on the NIH's website: https://www.nih.gov/opioid-crisis. Dr. Collins has since met with leaders of pharmaceutical and medical device companies to discuss potential collaborations with the NIH and FDA on some of the projects proposed at the meetings.

Christin is now serving on the planning committee and will be speaking at a follow-up meeting, commissioned by the NIH, to be held October 11-12, 2017 at the National Academies of Sciences, Engineering and Medicine. Additional information on the meeting can be viewed online:

http://www.nationalacademies.org/hmd/Activities/Research/NeuroForum/2017-OCT-11.aspx.

We invite you to read a recent blog post in which Christin Veasley shares some of the lessons she's learned from 30 years of living with chronic pain. 

Overlapping Conditions

Comments:

Login or Register to add Comment

In Treating TMJ

To view or order a free booklet about TMJ Disorders, visit the National Institutes of Health website.

U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
National Institutes of Health
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health